Mark Cuban Cost Plus Drug Company
Mark Cuban Cost Plus Drug Company is a Dallas-based, Public Benefit Corporation operating a direct-to-consumer mail-order pharmacy that sells 2,500-plus generic medications at manufacturer cost plus 15% markup and a $3-5 dispensing fee, serving 2 million members across all 50 U.S. states with documented 40-99% savings versus retail prices.
- Company typePrivate
- Founded2022
- HeadquartersDallas, United States
- Headcount51–100
- GTM typeB2B and B2C
- OfferingServices
What Mark Cuban Cost Plus Drug Company does
Mark Cuban Cost Plus Drug Company (MCCPDC), operating as a Public Benefit Corporation headquartered in Dallas, Texas, is a direct-to-consumer mail-order pharmacy built around a transparent cost-plus pricing model. The company sells more than 2,500 generic medications at manufacturer acquisition cost plus a 15% markup and a $3-$5 dispensing fee, publicly disclosing manufacturing costs and bypassing pharmacy benefit manager (PBM) spread pricing. Since launching in January 2022, MCCPDC has grown to over 2 million members and serves patients in all 50 U.S. states through URAC-accredited pharmacy facilities. The platform's pricing transparency has been cited by academic research as offering 40-99% savings versus retail pharmacy prices and potential Medicare Part D savings of $8.6 billion annually on generics alone.
The company's product surface has expanded well beyond the original consumer pharmacy. Core offerings now include the Cost Plus Drugs consumer platform, the Cost Plus Marketplace for Businesses (B2B procurement integrated with GraphiteRx and Bluesight for hospital systems serving 40 million+ patients annually), the SwiftyRx digital pharmacy platform with AI-driven prescription verification and insurance benefit checks, and a Dallas-based $11 million fill-finish manufacturing facility producing sterile injectables including carboplatin. The company has entered branded drugs via the BMS-Pfizer Eliquis partnership at $345 per 30-day supply, biosimilars via the launch of Starjemza (a Stelara biosimilar at approximately 98% below originator list price), and GLP-1 obesity therapeutics through the Eli Lilly Employer Connect platform offering Zepbound at $449. Distribution runs through direct e-commerce, employer benefit partnerships with Humana's CenterWell Pharmacy, SmithRx, WellDyne, and RxPreferred Benefits, federal channels via the TrumpRx portal, and retail grocery via Giant Eagle.
Revenue is generated primarily through per-prescription transaction fees (the 15% markup plus dispensing fee) and through employer/PBM channel partnerships. The company is privately held by founder Mark Cuban, structured as a Public Benefit Corporation, with no disclosed external venture capital. Strategic alliances in 2025-2026 include collaborations with Alchem Laboratories for AI/ML-based manufacturing of 86 essential medicines and the federal Equip-A-Pharma initiative. The company is positioned as a structural disruptor of the U.S. pharmaceutical distribution chain, with brand strength anchored by Mark Cuban's personal media presence and bipartisan political visibility.
Mark Cuban Cost Plus Drug Company firmographics
Firmographics- Name
- Mark Cuban Cost Plus Drug Company
- Legal name
- Mark Cuban Cost Plus Drug Company, PBC
- Website
- https://costplusdrugs.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Mark Cuban Cost Plus Drug Company is a Dallas-based, Public Benefit Corporation operating a direct-to-consumer mail-order pharmacy that sells 2,500-plus generic medications at manufacturer cost plus 15% markup and a $3-5 dispensing fee, serving 2 million members across all 50 U.S. states with documented 40-99% savings versus retail prices.
- Ownership category
- akta.pro rank
Mark Cuban Cost Plus Drug Company industry classification
Industry- Product category
- Online Pharmacy
- NAICS
- Pharmacies and Drug Retailers (456110), Pharmacies and Drug Retailers (45611), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Retail-Drug Stores And Proprietary Stores (5912), Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Discount Drugstores (Value-Focused Chain Pharmacies) (CRAEAHAA)
- akta.pro secondary industries
- Copay Assistance, Patient Support & Affordability Programs (HLAEAKAI), Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), Pharmacy Benefit/Channel Services (PSAO, 340B Admin, Chargebacks/Rebates Ops) (CRAOAHAK)
Keywords
Where Mark Cuban Cost Plus Drug Company is headquartered
LocationHeadquarters
- HQ city
- Dallas
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Mark Cuban Cost Plus Drug Company business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Supply Chain, Operations, Infrastructure, Technology or R&D, Personnel, Marketing or Sales
Revenue model
- Pharmacy Dispensing Fees: The company generates revenue through a transparent cost-plus pricing model: acquisition cost plus 15% markup plus a $3-5 dispensing fee. Patients pay for medications directly without insurance involvement for most generic prescriptions.
- Employer Benefit Solutions: Revenue generated through employer partnerships via SwiftyRx platform and CenterWell collaboration, providing prescription cost management solutions to employer groups facing rising healthcare costs
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Transaction based/ take rate | Pay-as-you-go | Standard Generic Medications - Cost Plus Pricing |
| Transaction based/ take rate | Pay-as-you-go | Brand-name Medications |
| Transaction based/ take rate | Monthly | Employer/PBM Partnership Pricing |
Go-to-market motion4 records
Distribution channels7 records
Marketing channels6 records
Mark Cuban Cost Plus Drug Company product offering
Product offeringCore offering
Mark Cuban Cost Plus Drug Company operates a direct-to-consumer online pharmacy (costplusdrugs.com) that dispenses more than 2,500 generic medications at a transparent cost-plus price equal to manufacturer acquisition cost plus a 15% markup plus a $3–$5 pharmacy dispensing fee, with mail delivery to all 50 U.S. states. It has expanded into a B2B Cost Plus Marketplace for Businesses, employer benefit solutions via the SwiftyRx AI platform (partnered with Humana CenterWell), branded/biosimilar offerings (Eliquis, Starjemza), and an $11 million Dallas manufacturing facility producing sterile injectables.
Product overview
Mark Cuban Cost Plus Drug Company operates as a direct-to-consumer pharmacy platform with a transparent cost-plus pricing model (manufacturer cost plus 15% markup plus $3-5 dispensing fee). The core offering is the consumer platform at costplusdrugs.com, which has grown to over 2,500 generic medications serving 2 million members with up to 80% savings versus retail pharmacies. The product portfolio includes the consumer platform, Cost Plus Marketplace for Businesses (B2B procurement), SwiftyRx (AI-powered employer prescription solutions), Dallas manufacturing facility for sterile injectables, and participation in federal initiatives like TrumpRx. The company also offers specialty medications including biosimilars like Starjemza and branded drugs like Eliquis through partnerships with pharmaceutical manufacturers. Key differentiators include URAC-accredited facilities, AI-powered prescription verification through SwiftyRx, and partnerships with CenterWell Pharmacy, GraphiteRx, and Medchat.ai.
Differentiator
Problem solved
Functional benefit
Brands
- SwiftyRx: AI-powered digital pharmacy platform that uses AI to verify prescriptions and check insurance benefits, integrated into employer prescription solutions.
Products and services
- Cost Plus Drugs Online Pharmacy
- Cost Plus Marketplace for Businesses
- SwiftyRx Digital Pharmacy Platform
- Starjemza (ustekinumab-hmny) Biosimilar
- Eliquis (apixaban) Direct Offering
- Employer Prescription Solutions (with Humana CenterWell)
- Zepbound (tirzepatide) Direct Distribution via Lilly Employer Connect
Quantifiable outcome
- Patients save up to 85% on out-of-pocket costs when buying directly from MCCPDC for prescriptions with copayments exceeding $15
- +4 more outcomes
Companies that use Mark Cuban Cost Plus Drug Company
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles4 records
Mark Cuban Cost Plus Drug Company technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability7 records
Feature4 records
Mark Cuban Cost Plus Drug Company partnerships and signals
Strategic signalPartnerships
16 partnerships are on record, tiered core, minor and flagship.
- SmithRxcoreMCCPDC integrated into SmithRx's best-in-class partner ecosystem for GLP-1 employer programs. The ecosystem leverages manufacturer-approved cash-pay pricing and transparent 100% pass-through PBM model, helping employers deliver sustainable GLP-1 coverage at scale with up to 70% cost savings.
- Elevance HealthminorIntegration of MCCPDC into Cost Plus Marketplace for businesses as Elevance Health expands access to affordable medications for employer groups and health plan members.
- TrumpRxcoreMCCPDC supplies 559 generic medications to the TrumpRx federal prescription drug pricing portal. Mark Cuban appeared at the White House alongside President Trump to announce the partnership, describing it as a 'special partnership' and noting bipartisan support for cheaper drugs across political lines.
- PaytientminorPartnership with healthcare affordability and payment solutions company. 72% of Paytient members report increased employer retention and 96% report reduced financial stress when using the platform.
- Humana CenterWell PharmacycoreDeepened partnership to develop end-to-end employer prescription solutions combining Cost Plus Drugs' low-cost transparent pricing and SwiftyRx technology with CenterWell's distribution capabilities. The collaboration aims to streamline patient onboarding, automate benefit checks, reduce medication costs for employers, and provide home delivery pharmacy services to Humana's eligible workforce enrolled in the Associate Benefit Plan.
- Bristol Myers Squibb-Pfizer AllianceflagshipCollaboration to make Eliquis (apixaban), the nation's most prescribed oral blood thinner, available on CostPlusDrugs.com starting April 27, 2026. Cash-paying patients can purchase a 30-day supply for $345, providing a reduced-cost direct purchasing option compared to standard pharmacy pricing.
- RxPreferred BenefitsminorCollaboration with RxPreferred's affiliate pharmacy network as part of their transparent business model featuring 100% pass-through pricing and no spread pricing for employer and health system clients.
- Eli LillycorePartner through Lilly Employer Connect platform enabling employers to provide Zepbound (tirzepatide) at $449 across all doses through MCCPDC's pharmacy network. Targets the gap where nearly half of commercially insured Americans lack obesity medication coverage.
- Alchem LaboratoriescoreStrategic alliance to develop essential medicine therapeutics and improve supply chain resiliency through automated manufacturing using AI and machine learning. Initial focus on lidocaine and diltiazem production, with collaboration to supply 86 essential medicines and medical countermeasures including critical care drugs and antimicrobials.
- GraphiteRxcoreExpanded partnership to enhance Cost Plus Marketplace for businesses, improving access to affordable medications for healthcare providers. Collaboration supports supply chain efficiency and serves over 40 million patients annually.
- Johnson & JohnsonflagshipMCCPDC launched Starjemza (ustekinumab-hmny), a biosimilar to J&J's Stelara, priced at approximately $360 per syringe (~$1,400-$2,200/year) compared to Stelara's ~$29,000/syringe list price - a 98% price reduction.
- Genentech/RocheminorGenentech's direct-to-patient program for Xofluza flu treatment partnered with MCCPDC and other pharmacies including Alto Pharmacy and Amazon Pharmacy, offering $50 cash pay option and same-day home delivery.
- Know WellnessminorPartnership to offer affordable prescriptions through Know Wellness' holistic health platform featuring AI-powered facial scans, at-home biomarker testing, and personalized supplements for accessible data-driven preventive care.
- Giant EagleminorPartnership with grocery chain Giant Eagle to lower prescription drug prices by offering transparent pricing model in five states, expanding consumer access to affordable medications through retail locations.
- WellDyneminorIntegration of MCCPDC into WellDyne's PBM routing strategy alongside Waltz Health's AI-powered platform, surfacing real-time alerts helping members find affordable medication options through automated claims adjudication.
- Morris & DicksonminorPartnership with specialty pharmaceutical distributor Morris & Dickson to improve access to injectable medications and supply chain efficiency. Aims to ensure steady availability of rare drugs and lower costs for healthcare providers.
Scale indicators10 records
Recent moves8 records
Expansion highlights6 records
Mark Cuban Cost Plus Drug Company competitors and assessment
Company assessmentDirect peers
- GoodRx: Publicly traded prescription drug price comparison and discount platform offering coupons and mail-order pharmacy (through Hey Doctor/Kroger partnership). Competes on the same uninsured/underinsured consumer segment with a coupon-driven rather than cost-plus model.
- Amazon Pharmacy: Amazon's online mail-order pharmacy offering transparent pricing on generics and integration with Prime for home delivery. Direct competitor to MCCPDC's DTC mail-order model with substantially larger capital base and existing customer reach.
- Ro: DTC telehealth platform with vertically integrated pharmacy offering branded and generic medications, including GLP-1 distribution. Operates a similar transparent pricing model and competes for the same high-deductible consumer segment.
- Capsule Pharmacy: Digital-first pharmacy offering free same-day delivery, transparent pricing, and personalized pharmacist support. Directly comparable mail-order and DTC pharmacy model targeting urban insured/underinsured consumers.
- Alto Pharmacy: Digital pharmacy with same-day delivery and transparent pricing. Competes directly on the insured/underinsured consumer with free delivery and care coordination, recently named alongside MCCPDC as a Genentech Xofluza partner.
- Hims & Hers Health: DTC telehealth and pharmacy platform offering prescription medications directly to consumers. Operates a similar mail-order model with transparent pricing and has expanded aggressively into GLP-1 and specialty medications, overlapping with MCCPDC's employer/PBM channels.
Broad incumbents
- Express Scripts (Cigna): One of the three largest U.S. PBMs administering prescription benefits for large employer groups and health plans. The spread-pricing practices of Express Scripts (and peers) are what MCCPDC's transparency model is designed to expose and replace.
- CVS Caremark: Major PBM and retail pharmacy chain offering both physical and mail-order prescription fulfillment. Operates the incumbent model that MCCPDC's cost-plus pricing directly competes against, especially in employer benefits.
- Optum Rx (UnitedHealth Group): Largest U.S. PBM administering pharmacy benefits for tens of millions of members. Represents the incumbent model MCCPDC is structurally bypassing, but is a potential integration/partner channel given Smith's pass-through PBM evolution.
Emerging players
- RxPreferred Benefits: Transparent PBM offering 100% pass-through pricing to employer and health system clients. Direct partner in MCCPDC's ecosystem and a structural peer in the transparent PBM space targeting the same employer RFP opportunities.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
Mark Cuban Cost Plus Drug Company social profiles
Digital presenceMark Cuban Cost Plus Drug Company compliance and trust
Trust signalCompliance1 record
Mark Cuban Cost Plus Drug Company financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mark Cuban Cost Plus Drug Company leadership team
Management profileNumber of profiles
Profiles2 records
Mark Cuban Cost Plus Drug Company funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mark Cuban Cost Plus Drug Company M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mark Cuban Cost Plus Drug Company
What does Mark Cuban Cost Plus Drug Company do?
Mark Cuban Cost Plus Drug Company operates a direct-to-consumer online pharmacy (costplusdrugs.com) that dispenses more than 2,500 generic medications at a transparent cost-plus price equal to manufacturer acquisition cost plus a 15% markup plus a $3–$5 pharmacy dispensing fee, with mail delivery to all 50 U.S. states. It has expanded into a B2B Cost Plus Marketplace for Businesses, employer benefit solutions via the SwiftyRx AI platform (partnered with Humana CenterWell), branded/biosimilar offerings (Eliquis, Starjemza), and an $11 million Dallas manufacturing facility producing sterile injectables.
Is Mark Cuban Cost Plus Drug Company a public or private company?
Mark Cuban Cost Plus Drug Company is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Mark Cuban Cost Plus Drug Company founded?
Mark Cuban Cost Plus Drug Company was founded in 2022. It employs 51 to 100 people.
Where is Mark Cuban Cost Plus Drug Company based?
Mark Cuban Cost Plus Drug Company is headquartered in Dallas, United States, in the North America region.
How does Mark Cuban Cost Plus Drug Company make money?
Two revenue lines are on record. Pharmacy Dispensing Fees are the primary driver. The others are employer Benefit Solutions.
Who are Mark Cuban Cost Plus Drug Company's main competitors?
Direct peers on record are GoodRx, Amazon Pharmacy, Ro, Capsule Pharmacy, Alto Pharmacy and Hims & Hers Health. Broad incumbents are Express Scripts (Cigna), CVS Caremark and Optum Rx (UnitedHealth Group). RxPreferred Benefits is listed as an emerging player.
Does Mark Cuban Cost Plus Drug Company have an API?
No public API is recorded for Mark Cuban Cost Plus Drug Company.
What industry is Mark Cuban Cost Plus Drug Company in?
Mark Cuban Cost Plus Drug Company's product category is Online Pharmacy. Its primary akta.pro industry code is CRAEAHAA, Discount Drugstores (Value-Focused Chain Pharmacies), with a secondary code of HLAEAKAI, Copay Assistance, Patient Support & Affordability Programs. Its NAICS code is 456110 and its SIC code is 5912.